Gilead Sciences announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The drug significantly normalized alkaline phosphatase (ALP), a critical liver disease marker, in patients with inadequately controlled PBC after 52 weeks. This supports Livdelzi's use in a broader patient group often underrepresented in trials. Gilead plans to present full data at a medical congress and engage regulators, advancing treatment options for PBC patients.
In the first half of 2026, smart beta strategies showed mixed results, with momentum and low-volatility funds lagging, while dividend growth funds struggled due to rising yields. However, funds emphasizing companies with strong free cash flow and hig...
RedHill Biopharma is actively pursuing collaborations to advance opaganib, an investigational oral drug, as a treatment for the current Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus subtype. Opaganib has demonstrated sig...
